Elena Antelmi1,2, Maria Stamelou3,4, Rocco Liguori1,5, Kailash P Bhatia2. 1. Department of Biomedical and Neuromotor Sciences Alma Mater Studiorum University of Bologna Bologna Italy. 2. Sobell Department of Motor Neuroscience and Movement Disorders University College London (UCL) Institute of Neurology London United Kingdom. 3. Second Department of Neurology University of Athens Athens Greece. 4. Neurology Clinic Philipps University Marburg Germany. 5. IRCCS Institute of Neurological Sciences Bologna Italy.
Abstract
BACKGROUND: Dopa-responsive dystonia (DRD) is a rare inherited dystonia, caused by an autosomal dominantly inherited defect in the gene GCH1 that encodes guanosine triphosphate cyclohydrolase 1. It catalyzes the first and rate-limiting enzyme in the biosynthesis of tetrahydrobiopterin, which is the essential co-factor for aromatic amino acid hydroxylases. Mutation results in the typical scenario of a young-onset lower-limb dystonia with diurnal fluctuations, concurrent or subsequent development of parkinsonism and excellent response to levodopa. Given the myriad functions of tetrahydrobiopterin, it is reasonable that other systems, apart from motor, would also be impaired. So far, non-motor symptoms have been overlooked and very few and often contrasting data are currently available on the matter. METHODS: Here by searching the Medline database for publications between 1971 to March 2015, we render an in-depth analysis of all published data on non-motor symptoms in DRD. RESULTS: Depression and subtle sleep quality impairment have been reported among the different cohorts, while current data do not support any alterations of the cardiologic and autonomic systems. However, there is debate about the occurrence of sleep-related movement disorders and cognitive function. Non-motor symptoms are instead frequently reported among the clinical spectrum of other neurotransmitter disorders which may sometimes mimic DRD phenotype, ie, DRD plus diseases. CONCLUSIONS: Further studies in larger and treatment-naïve cohorts are needed to better elucidate the extend of non-motor symptoms in DRD and also to consider treatment for these.
BACKGROUND: Dopa-responsive dystonia (DRD) is a rare inherited dystonia, caused by an autosomal dominantly inherited defect in the gene GCH1 that encodes guanosine triphosphate cyclohydrolase 1. It catalyzes the first and rate-limiting enzyme in the biosynthesis of tetrahydrobiopterin, which is the essential co-factor for aromatic amino acid hydroxylases. Mutation results in the typical scenario of a young-onset lower-limb dystonia with diurnal fluctuations, concurrent or subsequent development of parkinsonism and excellent response to levodopa. Given the myriad functions of tetrahydrobiopterin, it is reasonable that other systems, apart from motor, would also be impaired. So far, non-motor symptoms have been overlooked and very few and often contrasting data are currently available on the matter. METHODS: Here by searching the Medline database for publications between 1971 to March 2015, we render an in-depth analysis of all published data on non-motor symptoms in DRD. RESULTS: Depression and subtle sleep quality impairment have been reported among the different cohorts, while current data do not support any alterations of the cardiologic and autonomic systems. However, there is debate about the occurrence of sleep-related movement disorders and cognitive function. Non-motor symptoms are instead frequently reported among the clinical spectrum of other neurotransmitter disorders which may sometimes mimic DRD phenotype, ie, DRD plus diseases. CONCLUSIONS: Further studies in larger and treatment-naïve cohorts are needed to better elucidate the extend of non-motor symptoms in DRD and also to consider treatment for these.
Entities:
Keywords:
Dopa‐responsive dystonia; GTPCH1; dystonia; non motor symptoms in movement disorders
Authors: Michèl A Willemsen; Marcel M Verbeek; Erik-Jan Kamsteeg; Johanneke F de Rijk-van Andel; Alec Aeby; Nenad Blau; Alberto Burlina; Maria A Donati; Ben Geurtz; Padraic J Grattan-Smith; Martin Haeussler; Georg F Hoffmann; Hans Jung; Johannis B de Klerk; Marjo S van der Knaap; Fernando Kok; Vincenzo Leuzzi; Pascale de Lonlay; Andre Megarbane; Hugh Monaghan; Willy O Renier; Pierre Rondot; Monique M Ryan; Jürgen Seeger; Jan A Smeitink; Gerry C Steenbergen-Spanjers; Evangeline Wassmer; Bernhard Weschke; Frits A Wijburg; Bridget Wilcken; Dimitrios I Zafeiriou; Ron A Wevers Journal: Brain Date: 2010-04-29 Impact factor: 13.501
Authors: P DE Lonlay; M C Nassogne; A H van Gennip; A C van Cruchten; T Billatte de Villemeur; M Cretz; C Stoll; J M Launay; G C Steenberger-Spante; L P van den Heuvel; R A Wevers; J M Saudubray; N G Abeling Journal: J Inherit Metab Dis Date: 2000-12 Impact factor: 4.982
Authors: H Ichinose; T Ohye; E Takahashi; N Seki; T Hori; M Segawa; Y Nomura; K Endo; H Tanaka; S Tsuji Journal: Nat Genet Date: 1994-11 Impact factor: 38.330
Authors: Ailton C Alves Júnior; Maurício V Daker; Alexei M C Machado; Alan S Luna; Dirceu C Valladares Neto; Eugenia R Valadares Journal: Mol Genet Metab Rep Date: 2022-04-18